Implementing an electronic end-of-life chemotherapy utilization measure Published March 2020 Citation Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, and Meropol NJ. . Journal of Oncology Practice. . http://ascopubs.org/doi/abs/10.1200/JOP.18.00408 Authors:Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, and Meropol NJ Sources:Journal of Oncology Practice Share Posted inPublicationsTreatment patterns More publicationsASCO GUFebruary 2026Real-world (rw) first-line (1L) treatment (tx) patterns and overall survival (rwOS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) with frailty or comorbiditiesGrande E, Bamias A, Wit, R, et al. Publication summaryPublicationsTreatment patternsUrothelial cell carcinomaASCO GUFebruary 2026Real-world neoadjuvant therapy utilization and outcomes in patients with muscle-invasive bladder cancer ineligible for cisplatin treatmentPatel K, Zhao D, Hankinson E, et al.Publication summaryPublicationsTreatment patternsASCO GUFebruary 2026Beyond BRCA: Real-world outcomes with poly(ADP-ribose) polymerase inhibitors among patients with metastatic castration-resistant prostate cancer and homologous recombination repair mutationsHankinson E, Kerr B, Ward P, et al. Publication summaryPublicationsTreatment patternsProstate cancer